Lenangio 25mg

Lenangio 25 is a medication used to treat certain types of cancer, including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. It is a capsule that works by blocking the action of proteins that help cancer cells grow and multiply.

Composition:

Lenangio 25 contains Lenalidomide, a medication that is a thalidomide analog.

Indications:

Lenangio 25 is indicated for the treatment of:

1. Multiple myeloma (a type of blood cancer) in combination with dexamethasone
2. Mantle cell lymphoma (a type of blood cancer) in patients who have received at least one prior therapy
3. Follicular lymphoma (a type of blood cancer) in patients who have received at least one prior therapy

Mechanism of Action:

Lenalidomide works by:

1. Blocking the action of proteins that help cancer cells grow and multiply
2. Activating the immune system to attack cancer cells
3. Reducing the production of certain cytokines that promote inflammation

Dosage and Administration:

The recommended dosage of Lenangio 25 is:

• 25mg taken orally once daily, in combination with dexamethasone
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Lenangio 25 include:

1. Fatigue
2. Nausea and vomiting
3. Headache
4. Dizziness
5. Constipation
6. Diarrhea
7. Skin rash

Serious side effects can include:

1. Thrombocytopenia (low platelet count)
2. Neutropenia (low white blood cell count)
3. Anemia (low red blood cell count)
4. Hematologic toxicity (toxicity to the blood cells)
5. Increased risk of infections

Contraindications:

Lenangio 25 is contraindicated in patients with:

1. Hypersensitivity to Lenalidomide or other thalidomide analogs
2. Severe allergic reactions to human serum albumin or other components of the medication

Precautions:

1. Patients with a history of cardiac disease should be closely monitored while receiving Lenangio 25.
2. Patients with a history of kidney disease should be closely monitored while receiving Lenangio 25.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of fatigue or nausea.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.

It is also important to note that Lenalidomide is a pregnancy category X medication, meaning it has a high risk of causing harm to the fetus during pregnancy. Women who are pregnant or planning to become pregnant should avoid taking Lenalidomide. Men taking Lenalidomide should use effective contraception and talk to their doctor about the potential risks associated with exposure to the medication during pregnancy.